# Voxel-based spatial distribution of intracranial meningioma subtypes and their relationship to radiogenomic maps

**Authors:** Georgios Naros, Aldo Spolaore, Sophie Wang, Mykola Gorbachuk, Kathrin Machetanz, Benjamin Bender, Felix Behling, Jens Schittenhelm, Marcos Tatagiba

PMC · DOI: 10.1093/braincomms/fcag025 · Brain Communications · 2026-01-30

## TL;DR

This study maps the brain locations of different meningioma subtypes and shows how their positions relate to genetic patterns and tumor grades.

## Contribution

The study introduces voxel-based spatial templates that link meningioma subtypes to genetic mutations and tumor grades.

## Key findings

- Meningioma subtypes show distinct spatial preferences that align with known genetic mutation maps.
- Predictive modeling using spatial features achieved moderate accuracy in predicting histological subtypes and higher accuracy for tumor grading.
- Higher-grade meningiomas are more likely to occur in the frontoparietal transition zone.

## Abstract

Meningiomas are histologically and genetically heterogeneous tumors with varying anatomical distributions. While distinct genetic mutations have been associated with specific tumor locations, the spatial distribution of histological subtypes and their relationship to radiogenomic profiles remains poorly defined. Moreover, the predictive value of spatial information for histopathological classification and tumor grading has not yet been systematically explored. This study aimed to systematically analyze the anatomical predilection of histological meningioma subtypes and their concordance with known mutation-specific spatial patterns, and the predictive potential of voxel-based spatial features. We retrospectively analyzed 737 patients undergoing surgical resection of intracranial meningiomas. Preoperative magnetic resonance images were normalized to a common stereotactic space, and tumors were semi-automatically segmented. Voxel-based lesion-symptom mapping (VLSM) was performed to identify subtype-specific spatial clustering. Spatial distributions were compared with mutation maps from current literature using receiver operating characteristic analysis (AUC-ROC). Additionally, multinomial logistic regression models were applied to evaluate whether tumor localization could predict histological subtype and World Health Organization (WHO) grading. Histological subtypes showed distinct spatial preferences. Meningothelial meningiomas clustered in the anterior and middle skull base; fibrous and transitional types predominated in the convexity, falx, and tentorium; secretory tumors localized to the sphenoid wing and petroclival region; and atypical meningiomas were common in the anterior falx and frontal convexity. Psammomatous meningiomas displayed a broader distribution with involvement of the petrous bone and foramen magnum. AUC analysis revealed strong concordance between histological subtypes and mutation maps, confirming known histogenomic associations (e.g. KLF4/TRAF7 with secretory; NF2 with fibrous and transitional; SMO with meningothelial). No associations to any mutation map were observed for angiomatous, microcystic and metaplastic meningiomas. Predictive modeling based solely on spatial features achieved moderate accuracy for subtype classification and higher accuracy for WHO grade prediction. Meningioma subtypes show distinct, statistically robust anatomical predilections that align with known genetic mutation maps. Predictive modeling highlights that spatial features themselves hold diagnostic and prognostic value, linking anatomical localization to tumor biology and aggressiveness. The study introduces anatomically precise voxel-based templates that may improve radiogenomic classification and non-invasive genotype prediction.

Naros et al. report that voxel-based spatial mapping of 737 intracranial meningiomas reveals distinct anatomical clustering of histological subtypes and CNS grades. The study shows that higher-grade tumors preferentially occur at the frontoparietal transition zone, linking tumor location with underlying genetic drivers and enabling anatomically precise radiogenomic classification.

Graphical AbstractFor image description, please refer to the figure legend and surrounding text.

## Linked entities

- **Genes:** KLF4 (KLF transcription factor 4) [NCBI Gene 9314], TRAF7 (TNF receptor associated factor 7) [NCBI Gene 84231], NF2 (NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor) [NCBI Gene 4771], SMO (smoothened, frizzled class receptor) [NCBI Gene 6608]
- **Diseases:** meningioma (MONDO:0003057)

## Full-text entities

- **Genes:** PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, AKT3 (AKT serine/threonine kinase 3) [NCBI Gene 10000] {aka MPPH, MPPH2, PKB-GAMMA, PKBG, PRKBG, RAC-PK-gamma}, NF2 (NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor) [NCBI Gene 4771] {aka ACN, BANF, SCH, SWNV, merlin-1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, SMARCE1 (SWI/SNF related BAF chromatin remodeling complex subunit E1) [NCBI Gene 6605] {aka BAF57, CSS5}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, TRAF7 (TNF receptor associated factor 7) [NCBI Gene 84231] {aka CAFDADD, RFWD1, RNF119}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, PRKAR1A (protein kinase cAMP-dependent type I regulatory subunit alpha) [NCBI Gene 5573] {aka ACRDYS1, ADOHR, CAR, CNC, CNC1, PKR1}, BAP1 (BRCA1 associated deubiquitinase 1) [NCBI Gene 8314] {aka HUCEP-13, KURIS, TPDS1, UBM2, UCHL2, UVM2}, SUFU (SUFU negative regulator of hedgehog signaling) [NCBI Gene 51684] {aka BCNS2, JBTS32, PRO1280, SUFUH, SUFUXL}, POLR2A (RNA polymerase II subunit A) [NCBI Gene 5430] {aka NEDHIB, POLR2, POLRA, RPB1, RPBh1, RPO2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}, EP400 (E1A binding protein p400) [NCBI Gene 57634] {aka CAGH32, P400, TNRC12}, SMO (smoothened, frizzled class receptor) [NCBI Gene 6608] {aka CRJS, FZD11, Gx, PHLS, SMOH}, SMARCB1 (SWI/SNF related BAF chromatin remodeling complex subunit B1) [NCBI Gene 6598] {aka BAF47, CSS3, INI-1, INI1, MRD15, PPP1R144}, KMT2C (lysine methyltransferase 2C) [NCBI Gene 58508] {aka HALR, KLEFS2, MLL3}, KMT2D (lysine methyltransferase 2D) [NCBI Gene 8085] {aka AAD10, ALR, BCAHH, CAGL114, KABUK1, KMS}, PIK3CG (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma) [NCBI Gene 5294] {aka IMD97, PI3CG, PI3K, PI3Kgamma, PIK3, p110gamma}
- **Diseases:** brain lesion (MESH:D001927), Chordoid meningiomas (MESH:D008579), skull base meningiomas (MESH:D019292), Tumor (MESH:D009369), lesion (MESH:D009059), tumorigenesis (MESH:D063646), stroke (MESH:D020521)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12947794/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12947794/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12947794/full.md

---
Source: https://tomesphere.com/paper/PMC12947794